|
|
Volumn 23, Issue 6, 2015, Pages 1260-1275
|
|
Discovery and in vitro and in vivo profiles of N-ethyl-N-[2-[3-(5-fluoro-2-pyridinyl)-1H-pyrazol-1-yl]ethyl]-2-(2H-1,2,3-triazol-2-yl)-benzamide as a novel class of dual orexin receptor antagonist
a
a
a
a
a
a
a
a
a
a
a
a
a
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
2 (1H PYRAZOL 3 YL) 4 (TRIFLUOROMETHYL)PYRIDINE;
2 (1H PYRAZOL 3 YL) 5 (TRIFLUOROMETHYL)PYRIDINE;
2 (1H PYRAZOL 3 YL) 6 (TRIFLUOROMETHYL)PYRIDINE;
2 METHYL 6 (1H PYRAZOL 3 YL)PYRIDINE;
5 CHLORO N ETHYL N [2 [3 (5 FLUOROPYRIDIN 2 YL) 1H PYRAZOL 1 YL]ETHYL] 5 METHYL 2 (2H 1,2,3 TRIAZOL 2 YL)BENZAMIDE;
5 FLUORO 2 (1H PYRAZOL 3 YL)PYRIDINE;
BENZAMIDE DERIVATIVE;
FILOREXANT;
HORMONE RECEPTOR BLOCKING AGENT;
N ETHYL 2 [3 (4 FLUOROPHENYL) 1H PYRAZOL 1 YL]ETHANAMINE;
N ETHYL 2 [3 (5 FLUOROPYRIDIN 2 YL) 1H PYRAZOL 1 YL]ETHANAMINE;
N ETHYL 2 [3 (6 METHYLPYRIDIN 2 YL) 1H PYRAZOL 1 YL]ETHANAMINE;
N ETHYL 2 [3 [4 (TRIFLUOROMETHYL)PYRIDIN 2 YL] 1H PYRAZOL 1 YL]ETHANAMINE;
N ETHYL 2 [3 [5 (TRIFLUOROMETHYL)PYRIDIN 2 YL] 1H PYRAZOL 1 YL]ETHANAMINE;
N ETHYL 2 [3 [6 (TRIFLUOROMETHYL)PYRIDIN 2 YL] 1H PYRAZOL 1 YL]ETHANAMINE;
N ETHYL 5 FLUORO N [2 [3 (5 FLUOROPYRIDIN 2 YL) 1H PYRAZOL 1 YL]ETHYL] 5 METHYL 2 (2H 1,2,3 TRIAZOL 2 YL)BENZAMIDE;
N ETHYL 5 METHYL 2 (2H 1,2,3 TRIAZOL 2 YL) N [2 [3 [4 (TRIFLUOROMETHYL)PYRIDIN 2 YL] 1H PYRAZOL 1 YL]ETHYL]BENZAMIDE;
N ETHYL 5 METHYL 2 (2H 1,2,3 TRIAZOL 2 YL) N [2 [3 [5 (TRIFLUOROMETHYL)PYRIDIN 2 YL] 1H PYRAZOL 1 YL]ETHYL]BENZAMIDE;
N ETHYL 5 METHYL 2 (2H 1,2,3 TRIAZOL 2 YL) N [2 [3 [6 (TRIFLUOROMETHYL)PYRIDIN 2 YL] 1H PYRAZOL 1 YL]ETHYL]BENZAMIDE;
N ETHYL 5 METHYL [2 [3 (6 METHYLPYRIDIN 2 YL) 1H PYRAZOL 1 YL]ETHYL] 2 (2H 1,2,3 TRIAZOL 2 YL)BENZAMIDE;
N ETHYL N (2 HYDROXYETHYL) 5 METHYL 2 (2H 1,2,3 TRIAZOL 2 YL)BENZAMIDE;
N ETHYL N [2 [3 (4 FLUOROPHENYL) 1H PYRAZOL 1 YL]ETHYL] 5 METHYL 2 (2H 1,2,3 TRIAZOL 2 YL)BENZAMIDE;
N ETHYL N [2 [3 (5 FLUOROPYRIDIN 2 YL) 1H PYRAZOL 1 YL]ETHYL] 2 (2H 1,2,3 TRIAZOL 2 YL)BENZAMIDE;
N ETHYL N [2 [3 (5 FLUOROPYRIDIN 2 YL) 1H PYRAZOL 1 YL]ETHYL] 5 METHOXY 2 (2H 1,2,3 TRIAZOL 2 YL)BENZAMIDE;
N ETHYL N [2 [3 (5 FLUOROPYRIDIN 2 YL) 1H PYRAZOL 1 YL]ETHYL] 5 METHYL 2 (2H 1,2,3 TRIAZOL 2 YL)BENZAMIDE;
N ETHYL N [2 [3 (5 FLUOROPYRIDIN 2 YL) 1H PYRAZOL 1 YL]ETHYL] 5 METHYL 2 (PYRIMIDIN 2 YL)BENZAMIDE;
OREXIN RECEPTOR BLOCKING AGENT;
SB 674042;
SUVOREXANT;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
N-ETHYL-N-(2-(3-(5-FLUORO-2-PYRIDINYL)-1H-PYRAZOL-1-YL)ETHYL)-2-(2H-1,2,3-TRIAZOL-2-YL)BENZAMIDE;
OREXIN RECEPTOR ANTAGONIST;
TRIAZOLE DERIVATIVE;
ANIMAL CELL;
ANIMAL EXPERIMENT;
ARTICLE;
CONTROLLED STUDY;
DOG;
DRUG ABSORPTION;
DRUG BIOAVAILABILITY;
DRUG BLOOD LEVEL;
DRUG BRAIN LEVEL;
DRUG CLEARANCE;
DRUG DESIGN;
DRUG DISTRIBUTION;
DRUG ELIMINATION;
DRUG HALF LIFE;
DRUG IDENTIFICATION;
DRUG METABOLISM;
DRUG PENETRATION;
DRUG POTENCY;
DRUG SELECTIVITY;
DRUG SYNTHESIS;
HUMAN;
HUMAN CELL;
IN VITRO STUDY;
IN VIVO STUDY;
LIVER MICROSOME;
MALE;
NONHUMAN;
PHARMACOPHORE;
POLYSOMNOGRAPHY;
RAT;
SLEEP STAGE;
SLEEP WAKING CYCLE;
STRUCTURE ACTIVITY RELATION;
TIME TO MAXIMUM PLASMA CONCENTRATION;
ANIMAL;
CHEMICAL STRUCTURE;
CHEMISTRY;
CHO CELL LINE;
CRICETULUS;
DOSE RESPONSE;
DRUG DEVELOPMENT;
SYNTHESIS;
WISTAR RAT;
CANIS FAMILIARIS;
RATTUS;
ANIMALS;
BENZAMIDES;
CHO CELLS;
CRICETULUS;
DOGS;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG DISCOVERY;
HUMANS;
MALE;
MOLECULAR STRUCTURE;
OREXIN RECEPTOR ANTAGONISTS;
RATS;
RATS, WISTAR;
STRUCTURE-ACTIVITY RELATIONSHIP;
TRIAZOLES;
|
|
EID: 84923581204
PISSN: 09680896
EISSN: 14643391
Source Type: Journal
DOI: 10.1016/j.bmc.2015.01.044 Document Type: Article |
|
Times cited : (20)
|
|
References (20)
|
